Cystic Fibrosis from the Gastroenterologist's Perspective

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2016 Jan 22

PMID 26790364

Citations 51

Authors

Chee Y Ooi

Peter R Durie

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis is a life-limiting, recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Increased survival outcomes and the multisystem nature of the disease, including the involvement of hepatobiliary and gastrointestinal tracts, now require the need for more extensive knowledge and expertise in cystic fibrosis among gastroenterologists. Manifestations are either a direct consequence of the primary defect in cystic fibrosis or a secondary complication of the disease or therapy. Adult patients with cystic fibrosis also have an increased risk of malignancy in the gastrointestinal and pancreatico-biliary tracts compared with the general population. Novel treatments that target the basic defects in the CFTR protein have emerged, but to date not much is known about their effects on the gastrointestinal and hepatobiliary systems. The introduction of such therapies has provided new opportunities for the application of intestinal endpoints in clinical trials and the understanding of underlying disease mechanisms that affect the gut in cystic fibrosis.

Citing Articles

Enrichment of rare CFTR variants in Finnish patients with congenital chloride diarrhea.

Wedenoja S, Ritari J, Partanen J, Kere J, Kolho K PLoS One. 2025; 20(2):e0318249.

PMID: 39992989 PMC: 11849811. DOI: 10.1371/journal.pone.0318249.

Genetics of liver disease in adults.

Konkwo C, Chowdhury S, Vilarinho S Hepatol Commun. 2024; 8(4).

PMID: 38551385 PMC: 10984672. DOI: 10.1097/HC9.0000000000000408.

Scoring Abdominal Symptoms in People with Cystic Fibrosis.

Tabori H, Barucha A, Zagoya C, Duckstein F, Dunay G, Sadrieh P J Clin Med. 2024; 13(6).

PMID: 38541878 PMC: 10971656. DOI: 10.3390/jcm13061650.

Association between Dietary Intake and Faecal Microbiota in Children with Cystic Fibrosis.

Viteri-Echeverria J, Calvo-Lerma J, Ferriz-Jordan M, Garriga M, Garcia-Hernandez J, Heredia A Nutrients. 2023; 15(24).

PMID: 38140272 PMC: 10745571. DOI: 10.3390/nu15245013.

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.

Mainz J, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L Front Pharmacol. 2023; 14:1167407.

PMID: 38026920 PMC: 10658783. DOI: 10.3389/fphar.2023.1167407.

References

Witters P, Libbrecht L, Roskams T, De Boeck K, Dupont L, Proesmans M . Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology. 2011; 53(3):1064-5. DOI: 10.1002/hep.24183. View

Rath T, Menendez Menendez K, Kugler M, Hage L, Wenzel C, Schulz R . TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. Dig Liver Dis. 2012; 44(9):780-7. DOI: 10.1016/j.dld.2012.04.008. View

Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E . Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011; 10 Suppl 2:S86-102. DOI: 10.1016/S1569-1993(11)60014-3. View

ESTERLY J, Oppenheimer E . Observations in cystic fibbrosis of the pancreas. I. The gallbladder. Bull Johns Hopkins Hosp. 1962; 110:247-55. View

Gottlieb R, Dosanjh A . Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. Proc Natl Acad Sci U S A. 1996; 93(8):3587-91. PMC: 39654. DOI: 10.1073/pnas.93.8.3587. View

Maisonneuve P, FitzSimmons S, Neglia J, Campbell 3rd P, Lowenfels A . Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003; 95(5):381-7. DOI: 10.1093/jnci/95.5.381. View

Flass T, Tong S, Frank D, Wagner B, Robertson C, Kotter C . Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015; 10(2):e0116967. PMC: 4319904. DOI: 10.1371/journal.pone.0116967. View

Bartlett J, Friedman K, Ling S, Pace R, Bell S, Bourke B . Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009; 302(10):1076-83. PMC: 3711243. DOI: 10.1001/jama.2009.1295. View

Shields M, Levison H, Reisman J, Durie P, Canny G . Appendicitis in cystic fibrosis. Arch Dis Child. 1991; 66(3):307-10. PMC: 1792851. DOI: 10.1136/adc.66.3.307. View

10.

Sheth S, Shea J, Bishop M, Chopra S, Regan M, Malmberg E . Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet. 2003; 113(3):286-92. DOI: 10.1007/s00439-003-0963-z. View

11.

Ooi C, Durie P . Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros. 2012; 11(5):355-62. DOI: 10.1016/j.jcf.2012.05.001. View

12.

Dray X, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Hubert D . Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004; 2(6):498-503. DOI: 10.1016/s1542-3565(04)00169-7. View

13.

Quinton P . Chloride impermeability in cystic fibrosis. Nature. 1983; 301(5899):421-2. DOI: 10.1038/301421a0. View

14.

Ooi C, Dupuis A, Ellis L, Jarvi K, Martin S, Ray P . Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?. Thorax. 2013; 69(3):254-60. DOI: 10.1136/thoraxjnl-2013-203832. View

15.

Lindor K, Kowdley K, Luketic V, Harrison M, McCashland T, Befeler A . High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50(3):808-14. PMC: 2758780. DOI: 10.1002/hep.23082. View

16.

Colombo C, Castellani M, Balistreri W, Seregni E, Assaisso M, Giunta A . Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992; 15(4):677-84. DOI: 10.1002/hep.1840150421. View

17.

De Lisle R . Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2007; 293(1):G104-11. DOI: 10.1152/ajpgi.00548.2006. View

18.

Jafari S, Mehdizadeh-Hakkak A, Kianifar H, Hebrani P, Ahanchian H, Abbasnejad E . Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran J Pediatr. 2014; 23(6):669-74. PMC: 4025125. View

19.

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

20.

Smyth R, van Velzen D, Smyth A, Lloyd D, Heaf D . Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet. 1994; 343(8889):85-6. DOI: 10.1016/s0140-6736(94)90817-6. View